The biotechnology sector is in a “bubble”, pushing prices for medium-sized companies with experimental drugs in late-stage development out of reach, the chief executive of drugmaker Roche said on Tuesday. “I think this bubble will burst at some point,” Severin Schwan told Reuters in an interview during a visit to London. The Swiss company […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
An experimental cannabis drug for treating schizophrenia, developed by UK-based GW Pharmaceuticals Plc, was found to be superior to a placebo in a mid-stage trial. The company’s UK-listed shares jumped 12.5 percent, while U.S.-listed shares were up 10 pct. The drug, cannabidiol, was tested in 88 patients with schizophrenia, who had failed to respond to […]
Analysts are confident the U.S. Food and Drug Administration (FDA) will soon approve Novo Nordisk’s new long-lasting insulin drug Tresiba — just as they were before the drug was first rebuffed two years ago. Tresiba is considered as a future blockbuster for the Danish company, the Nordic region’s most valuable, but the U.S. regulator asked […]
The U.S. Food and Drug Administration (FDA) advised Waltham, Mass.-based FORUM Pharmaceuticals to halt its clinical trials of encenicline for Alzheimer’s disease yesterday. The FDA cited a small number of serious gastrointestinal (GI) side effects in the studies. As a result, FORUM halted the trial, discontinuing the medication and no new patients will be recruited […]
Drug developer XenoPort Inc said its experimental drug was effective in treating psoriasis, a chronic inflammatory disease of the skin. XenoPort’s shares jumped 19 percent to $8.00 in premarket trading on Tuesday after the company said the oral drug met the main goal in a mid-stage trial. XenoPort said it expected to start late-stage trials […]
Hayward, Calif.-based Anthera Pharmaceuticals, Inc. (ANTH) announced today that its Japanese development partner, Zenyaku, had ended a December 2014 Collaboration and License Agreement. The deal will terminate Jan. 7, 2016. The original deal was for the development of blisibimod in Japan. Blisibimod is a selective peptibody antagonist of the B-cell activating factor (BAFF) cytokine. It […]
Sony Corp and Olympus Corp said they plan to unveil an ultra high-definition surgical endoscope this week, the first major product from a joint venture formed three years ago. The product allows physicians to view clearer, more instant images of internal organs, aiding precision during surgical procedures, the medical device makers told Reuters ahead of […]
Mylan NV on Monday officially took its takeover bid directly to shareholders of Perrigo Co. (PRGO 0.88 %) after the company’s board and management publicly rebuffed previous advances. Mylan is offering $75 in cash and 2.3 shares of Mylan for each Perrigo share held, valued at about $187 based on Friday’s closing price. Perrigo’s shares […]
The U.S. Food and Drug Administration (FDA) has banned imports from another India-based drug manufacturing plant over quality control concerns, making it the 10th site in the country this year to face such action. The FDA’s “import alert” on Mumbai-based Polydrug Laboratories Pvt Ltd’s Ambernath manufacturing plant comes two months after Canada banned the […]
Raptor Pharmaceutical Corp lost more than a third of its market value after the company said it did not plan to develop its liver drug, which failed to meet the main goal in a second mid-stage study. The company’s shares plunged 35.5 percent to $7.61 in premarket trading on Monday. The study was testing the […]